Cart
sales@molnova.com
Monastrol
CAS No. 254753-54-3
Monastrol( Monastrol )
Catalog No. M19323 CAS No. 254753-54-3
Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMonastrol
-
NoteResearch use only, not for human use.
-
Brief DescriptionMonastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5.
-
DescriptionMonastrol is a kinesin Eg5 inhibitor. Induction of apoptosis by monastrol is independent of the spindle checkpoint. Monastrol binds to the KSP-ADP complex, forming a KSP-ADP- monastrol ternary complex, which cannot bind to microtubules productively and cannot undergo further ATP-driven conformational changes.
-
In Vitro——
-
In Vivo——
-
SynonymsMonastrol
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEg5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number254753-54-3
-
Formula Weight292.35
-
Molecular FormulaC14H16N2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCOC(=O)C1=C(NC(=S)NC1C2=CC(=CC=C2)O)C
-
Chemical Nameethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cochran JC, et al. Monastrol inhibition of the mitotic kinesin Eg5. J BiolChem. 2005 Apr 1;280(13):12658-67.
molnova catalog
related products
-
O-Nornuciferine
O-Nornuciferine reveals distinct in vitro hERG blockages measured in HEK293 cells with the IC50 value of 2.89 uM.
-
AG-825
AG-825（Tyrphostin C15） is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (Tyrphostin C15) inhibits HER2 and shows anticancer activity in a mouse xenograft model of breast cancer.
-
Vandetanib
Vandetanib is an orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability.
